KR20190122664A - 헌팅턴 병 치료를 위한 PPARγ효현제 - Google Patents

헌팅턴 병 치료를 위한 PPARγ효현제 Download PDF

Info

Publication number
KR20190122664A
KR20190122664A KR1020197023202A KR20197023202A KR20190122664A KR 20190122664 A KR20190122664 A KR 20190122664A KR 1020197023202 A KR1020197023202 A KR 1020197023202A KR 20197023202 A KR20197023202 A KR 20197023202A KR 20190122664 A KR20190122664 A KR 20190122664A
Authority
KR
South Korea
Prior art keywords
subject
disease
huntington
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197023202A
Other languages
English (en)
Korean (ko)
Inventor
바바라 핀크
로렌스 스타인만
Original Assignee
코히러스 바이오사이언시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코히러스 바이오사이언시스, 인크. filed Critical 코히러스 바이오사이언시스, 인크.
Publication of KR20190122664A publication Critical patent/KR20190122664A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197023202A 2017-01-18 2018-01-18 헌팅턴 병 치료를 위한 PPARγ효현제 Ceased KR20190122664A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447741P 2017-01-18 2017-01-18
US62/447,741 2017-01-18
PCT/US2018/014240 WO2018136635A1 (en) 2017-01-18 2018-01-18 Pparϒ agonist for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
KR20190122664A true KR20190122664A (ko) 2019-10-30

Family

ID=62908392

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197023202A Ceased KR20190122664A (ko) 2017-01-18 2018-01-18 헌팅턴 병 치료를 위한 PPARγ효현제

Country Status (13)

Country Link
US (1) US20190350918A1 (https=)
EP (1) EP3570841A4 (https=)
JP (1) JP2020505448A (https=)
KR (1) KR20190122664A (https=)
CN (1) CN110461330A (https=)
AU (1) AU2018210165A1 (https=)
BR (1) BR112019014529A2 (https=)
CA (1) CA3050104A1 (https=)
EA (1) EA201991716A1 (https=)
IL (1) IL268008A (https=)
MX (1) MX2019008535A (https=)
SG (1) SG11201906644YA (https=)
WO (1) WO2018136635A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895541B2 (en) * 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP2008515978A (ja) * 2004-10-13 2008-05-15 ユニバーシティ オブ コネチカット カンナビネルジック脂質リガンド
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
EP2448412B1 (en) * 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途

Also Published As

Publication number Publication date
IL268008A (en) 2019-09-26
CA3050104A1 (en) 2018-07-26
BR112019014529A2 (pt) 2020-02-27
EA201991716A1 (ru) 2020-02-04
EP3570841A4 (en) 2020-08-19
MX2019008535A (es) 2019-12-02
EP3570841A1 (en) 2019-11-27
WO2018136635A1 (en) 2018-07-26
JP2020505448A (ja) 2020-02-20
CN110461330A (zh) 2019-11-15
US20190350918A1 (en) 2019-11-21
AU2018210165A1 (en) 2019-08-01
SG11201906644YA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
RS59048B1 (sr) Terapeutski agensi za neurodegenerativne bolesti
US20200188358A1 (en) Methods for the treatment of depression
WO2011019845A1 (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
Garcia-Malo et al. Restless legs syndrome and other common sleep-related movement disorders
JPWO2007046347A1 (ja) 筋萎縮性側索硬化症患者の運動神経保護用医薬
EP3697399B1 (en) Therapeutic agents for use in the treatment of restless leg syndrome
KR20190122664A (ko) 헌팅턴 병 치료를 위한 PPARγ효현제
JP2002541198A (ja) 失禁の治療法
US6462089B1 (en) Method for correcting the vigilance disorders associated with myopathies
US11660279B2 (en) Therapeutic agents for treating restless leg syndrome
TWI494106B (zh) Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途
Freeman et al. ICU management of patients with Parkinson's disease or Parkinsonism
JP2001523724A (ja) 運動ニューロン病および脱髄病を治療するためのシチコリン
PFEFFERBAUM et al. Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma
CN108025003B (zh) 前额叶皮质处理病症，步态和肢体障碍治疗
ES2203210T3 (es) Uso de un agonista de receptor nicotinico para la fabricacion de un medicamento para el tratamiento del trastorno obsesivo compulsivo.
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
WO2024211310A1 (en) Methods of dosing spinogenic compounds
KR20260023584A (ko) 다발성 경화증의 치료를 위한 이보가인
Cassidy rehabilitation of patients with traumatic brain injury
US20200054664A1 (en) Metabolic supplement formulation and methods of use for treating depression and anxiety
HK40036165A (en) Acetyl-leucine for use in treating restless leg syndrome
AU2018371628A1 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
BR112020007657B1 (pt) Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)